Gilead Says Second HIV Drug Combination Fails
- Share via
From Bloomberg News
Gilead Sciences Inc. said a second attempt at combining its Truvada HIV drug into a single pill with Bristol-Myers Squibb Co.’s Sustiva failed, delaying an application for Food and Drug Administration approval until next year.
Shares of Foster City, Calif.-based Gilead fell 4.7% in after-hours trading after closing at $42.68, up 57 cents.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
